Lifecome Biochemistry Co.,Ltd.
SZSE:002868.SZ
24.39 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 507.005 | 329.85 | 363.386 | 308.145 | 303.76 | 344.292 | 375.411 | 401.49 | 385.613 | 295.776 | 297.151 | 306.556 |
| Cost of Revenue
| 552.432 | 339.104 | 303.799 | 214.62 | 202.733 | 225.382 | 223.579 | 243.989 | 243.02 | 210.348 | 211.256 | 204.065 |
| Gross Profit
| -45.427 | -9.254 | 59.588 | 93.526 | 101.027 | 118.91 | 151.832 | 157.502 | 142.593 | 85.428 | 85.894 | 102.491 |
| Gross Profit Ratio
| -0.09 | -0.028 | 0.164 | 0.304 | 0.333 | 0.345 | 0.404 | 0.392 | 0.37 | 0.289 | 0.289 | 0.334 |
| Reseach & Development Expenses
| 27.531 | 21.825 | 24.821 | 19.913 | 18.55 | 14.567 | 14.107 | 13.171 | 13.016 | 11.771 | 14.544 | 11.719 |
| General & Administrative Expenses
| 11.244 | 5.946 | 4.985 | 5.334 | 2.999 | 3.064 | 4.434 | 3.433 | 3.505 | 2.365 | 26.731 | 21.188 |
| Selling & Marketing Expenses
| 15.926 | 10.815 | 14.969 | 11.885 | 21.186 | 20.829 | 20.528 | 22.238 | 20.969 | 16.445 | 15.464 | 16.408 |
| SG&A
| 27.171 | 16.761 | 19.954 | 17.219 | 24.184 | 23.893 | 24.962 | 25.67 | 24.474 | 18.81 | 42.194 | 37.595 |
| Other Expenses
| -4.762 | 12.109 | 15.527 | 12.625 | 8.657 | -0.074 | -0.311 | 7.824 | 6.42 | 3.8 | 10.458 | 1.67 |
| Operating Expenses
| 82.74 | 50.695 | 60.302 | 49.757 | 51.391 | 47.035 | 46.625 | 53.607 | 51.247 | 41.623 | 44.094 | 39.42 |
| Operating Income
| -236.132 | -133.76 | -21.291 | 48.023 | 66.985 | 87.197 | 100.573 | 104.31 | 87.849 | 32.866 | 28.202 | 48.617 |
| Operating Income Ratio
| -0.466 | -0.406 | -0.059 | 0.156 | 0.221 | 0.253 | 0.268 | 0.26 | 0.228 | 0.111 | 0.095 | 0.159 |
| Total Other Income Expenses Net
| -112.727 | -0.351 | -11.059 | 0.419 | -0.979 | 15.249 | -4.945 | 4.346 | 0.462 | -7.189 | -3.141 | -12.783 |
| Income Before Tax
| -240.893 | -134.11 | -32.35 | 48.442 | 66.007 | 87.123 | 100.263 | 108.241 | 91.808 | 36.615 | 38.659 | 50.287 |
| Income Before Tax Ratio
| -0.475 | -0.407 | -0.089 | 0.157 | 0.217 | 0.253 | 0.267 | 0.27 | 0.238 | 0.124 | 0.13 | 0.164 |
| Income Tax Expense
| -18.276 | -11.389 | -5.906 | 5.506 | 9.175 | 12.434 | 14.338 | 15.88 | 13.704 | 5.165 | 5.689 | 7.047 |
| Net Income
| -221.818 | -122.722 | -26.444 | 43.208 | 56.966 | 74.689 | 85.925 | 92.361 | 78.105 | 31.449 | 32.97 | 43.241 |
| Net Income Ratio
| -0.438 | -0.372 | -0.073 | 0.14 | 0.188 | 0.217 | 0.229 | 0.23 | 0.203 | 0.106 | 0.111 | 0.141 |
| EPS
| -1.44 | -0.8 | -0.17 | 0.28 | 0.37 | 0.48 | 0.6 | 0.79 | 0.67 | 0.27 | 0.28 | 0.37 |
| EPS Diluted
| -1.44 | -0.8 | -0.17 | 0.28 | 0.37 | 0.48 | 0.6 | 0.79 | 0.67 | 0.27 | 0.28 | 0.37 |
| EBITDA
| -51.781 | -4.213 | 12.65 | 83.782 | 97.979 | 119.552 | 131.145 | 143.053 | 131.3 | 75.37 | 42.814 | 68.152 |
| EBITDA Ratio
| -0.102 | -0.013 | 0.035 | 0.272 | 0.323 | 0.347 | 0.349 | 0.356 | 0.34 | 0.255 | 0.144 | 0.222 |